Related Experiment Video

Updated: Jul 7, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment

Charlotte Marie Niemeyer1, Christian Peter Kratz

  • 1Department of Paediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany. charlotte.niemeyer@uniklinik-freiburg.de

British Journal of Haematology
|February 28, 2008
PubMed

Insights

Juvenile myelomonocytic leukaemia (JMML) in children may stem from RAS pathway mutations. Research into inherited bone marrow failure syndromes could illuminate myelodysplastic syndromes (MDS) development.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukaemia (JMML) are rare pediatric hematopoietic stem cell diseases.
  • MDS pathogenesis is largely unknown, but JMML is linked to RAS signaling pathway mutations.
  • Hematopoietic stem cell transplantation (HSCT) offers a cure for over half of affected children.

Purpose of the Study:

  • To explore the underlying causes of pediatric MDS and JMML.
  • To investigate the role of RAS signaling pathway mutations in JMML.
  • To understand how inherited bone marrow failure syndromes may inform MDS pathogenesis.

Main Methods:

  • Review of clinical, genetic, and laboratory evidence.
  • Analysis of signaling pathway components.
  • Study of inherited syndromes predisposing to MDS.

Main Results:

  • Evidence suggests JMML involves aberrant RAS signal transduction due to mutations.
  • Genetic conditions predisposing to MDS may offer insights into disease development.
  • HSCT is a curative option for a significant proportion of pediatric MDS/JMML patients.

Conclusions:

  • JMML pathogenesis is partly explained by RAS pathway mutations.
  • Further research into inherited bone marrow failure syndromes is crucial for understanding MDS.
  • Understanding genetic predispositions is key to advancing pediatric hematopoietic stem cell disease research.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...